The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections ... People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

US President Donald Trump has backed down from setting high tariffs on pharmaceuticals and semiconductors imported from the ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

This is but a fact that obesity drugs are only going to get more accessible for Indians post March 2026. But whether they make us healthier depends on how we use them. If they become another ...